Clinical trial NCT00003926 (phase 1, status: terminated)
Conditions: brain and central nervous system tumors, childhood germ cell tumor, chordoma, kidney cancer, liver cancer, neuroblastoma, ovarian cancer, retinoblastoma, sarcoma
ICD codes: F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2, D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa
SMILES: NCCCNCCSP(O)(O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1
Reason stopped: 
    withdrawn due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed high-risk or relapsed solid tumors or brain tumors,
             including:

               -  Metastatic or relapsed Ewing's sarcoma

               -  Metastatic or relapsed rhabdomyosarcoma

               -  Refractory Wilms' tumor

               -  Diffuse anaplastic Wilms' tumor

               -  Stage III or IV neuroblastoma

               -  Recurrent retinoblastoma

               -  Metastatic or relapsed germ cell tumors

               -  Metastatic or relapsed other soft tissue sarcomas

               -  Small cell ovarian sarcoma

               -  Metastatic or relapsed primitive neuroectodermal tumors of the bone

               -  Recurrent brain tumors

               -  Desmoplastic small round cell tumors

               -  Recurrent or metastatic chordomas

               -  Metastatic or relapsed hepatoblastoma

          -  Patients receive peripheral blood stem cell transplantation only if in complete
             remission or in very good partial remission with no disease progression

          -  Must have radiologic, nuclear image, or histologic verification of relapse

          -  Age 1 to 45

          -  Performance status:Karnofsky 70-100%

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin count at least 10 g/dL

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  SGOT or SGPT less than 2.5 times ULN

          -  Creatinine less than 2 times ULN

          -  Creatinine clearance greater than 70 mL/min

          -  Cardiac shortening fraction greater than 30%

          -  Cardiac ejection fraction greater than 45%

          -  At least 1 week since prior hematopoietic growth factor and recovered

          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  Recovered from any prior therapy

        Exclusion Criteria:

          -  Osteogenic sarcoma

          -  Less than 4 months

          -  Uncontrolled bleeding

          -  Congestive heart failure

          -  Uncontrolled hypertension

          -  Asthma

          -  Pregnant or nursing

          -  Uncontrolled metabolic disease

          -  Active severe infection

          -  Allergy to aminothiol compounds

          -  Prior bone marrow transplantation

          -  Other concurrent investigational agents